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What is already known about this topic? 35 
 Pain is prevalent among people with advanced dementia approaching the end of life 36 
but is challenging to identify and treat in patients with profound loss of 37 
communication who are unable to report the presence, nature and intensity of their 38 
pain. 39 
 People with advanced dementia are at risk of under-treatment or suboptimal treatment 40 
of pain as they approach the end of life.  41 
 Untreated pain, or suboptimal treatment of pain, often have deleterious effects on 42 
people with advanced dementia including: delirium, sleep disturbance, increased 43 
confusion and exacerbation of neuropsychiatric symptoms. 44 
 45 
 46 
What this paper adds? 47 
 This study is the first to explore and describe the complexities and challenges 48 
experienced by physicians when prescribing for and managing pain in people with 49 
advanced dementia who are approaching the end of life, the impact of these challenges 50 
on prescribing and treatment approaches, and the strategies used by physicians to 51 
overcome these challenges.   52 
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 Physicians’ prescribing and treatment decisions were shaped by patients’ 53 
comorbidities, ageing physiology, existing medication regimens, physical and 54 
cognitive impairments and health status. 55 
 Physicians from primary, secondary and hospice care settings made use of knowledge 56 
networks across specialties (e.g. palliative care, psychiatry etc.) to inform prescribing 57 
and treatment approaches and to overcome the challenges of pain management in this 58 
vulnerable patient population. 59 
  60 
 61 
 62 
Implications for practice, theory or policy? 63 
 Physicians’ goals in end of life care for people with dementia included optimal pain 64 
management. However, the complexity of the patient population can make optimal 65 
pain management challenging to achieve in practice. 66 
 Physicians’ narratives revealed an interactive interface across primary, secondary and 67 
hospice care settings and across medical specialties through which knowledge and 68 
expertise were exchanged to allow palliative and non-palliative doctors to overcome 69 
the challenges of pain management.  70 
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 Promoting cross-specialty knowledge exchange and mentoring can empower non-71 
palliative care physicians to confidently and effectively manage complex palliative 72 
care patients in their respective settings.  73 
 74 
Abstract  75 
Background: Pain management is a cornerstone of palliative care. The clinical issues 76 
encountered by physicians when managing pain in patients dying with advanced 77 
dementia, and how these may impact on prescribing and treatment, are unknown. Aim: 78 
To explore physicians’ experiences of pain management for patients nearing the end of 79 
life, the impact of these on prescribing and treatment approaches, and the methods 80 
employed to overcome these challenges. Design:  Qualitative, semi-structured interview 81 
study exploring: barriers to and facilitators of pain management, prescribing and 82 
treatment decisions, and training needs. Thematic analysis was used to elicit key themes. 83 
Settings/Participants: Twenty-three physicians, responsible for treating patients with 84 
advanced dementia approaching the end of life, were recruited from primary care (n=9), 85 
psychiatry (n=7) and hospice care (n=7). Results: Six themes emerged: diagnosing pain, 86 
complex prescribing and treatment approaches, side-effects and adverse events, route of 87 
administration, importance of sharing knowledge and training needs. Knowledge 88 
exchange was often practised through liaison with physicians from other specialties. 89 
Cross-specialty mentoring, and the creation of knowledge networks were believed to 90 
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improve pain management in this patient population. Conclusions: Pain management in 91 
end-stage dementia is complex, requiring cross-population of knowledge between 92 
palliative care specialists and non-specialists, in addition to collateral information 93 
provided by other health professionals and patients’ families. Regular, cost- and time-94 
effective mentoring and ongoing professional development are perceived to be essential 95 
in empowering physicians to meet clinical challenges in this area. 96 
 97 
Keywords: Dementia; Pain; Pain Management; Physicians; Palliative Care; Frail Elderly 98 
 99 
Introduction  100 
Dementia is an increasingly challenging global public health concern (1). Worldwide 101 
prevalence has reached 46.8 million (2), and projections estimate 74.4 million people 102 
living with dementia by 2030 (3). In the United Kingdom (UK), 850,000 people are living 103 
with dementia, 19,765 of whom reside in Northern Ireland (NI) (4). The need for 104 
appropriate palliative care to manage symptoms, including pain, for people living and 105 
dying with dementia is a focus of dementia care strategy in public health policy and is a 106 
recognised human right (5-7).  107 
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Pain is commonly experienced by people with dementia towards the end of life and is 108 
predominantly due to the prevalence of age-associated conditions (e.g. osteo- and 109 
rheumatoid arthritis, joint disorders, infection), chronic comorbidities (e.g. heart disease, 110 
cancer, diabetes) and distressing symptoms including: nausea, dehydration, dysphagia 111 
and dyspnoea (8-12). The deleterious impact of undetected, unresolved or untreated pain 112 
in people with moderate and advanced dementia has been reported to result in: delirium, 113 
sleep disturbance, increased confusion and exacerbation of neuropsychiatric symptoms 114 
(13-20). Previous studies have reported inconsistent approaches to pain management for 115 
people with dementia (21-24), primarily due to difficulty assessing and diagnosing pain, 116 
and lack of clinical data to guide prescribing for patients approaching the end of life (12, 117 
25-27). The under-representation of older adults in clinical trials of analgesics may mean 118 
that key outcome measures including toxicity and drug action do not accurately reflect 119 
their use in patients with multiple comorbidities and significant physical frailty, and can 120 
lead to variability in treatment outcomes (28-33). The inclusion of older, comorbid adults 121 
in clinical drug trials is attracting increasing research interest (34-36). Little is known 122 
about the challenges encountered by physicians when managing pain in people with 123 
advanced dementia nearing the end of life; even less is known about the strategies and 124 
resources used to overcome these challenges. This study aimed to elucidate this 125 
information as part of a wider programme of research into assessing and managing pain 126 
in this complex patient group. 127 
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Aim  128 
To explore physicians’ perspectives of the barriers to managing pain in patients nearing 129 
the end of life, the impact of these on patient outcomes and the methods employed to 130 
overcome these challenges. 131 
 132 
Methods  133 
 134 
Setting/Participants 135 
Physicians from primary, secondary and hospice care settings were recruited from general 136 
practice surgeries (n=5), hospices (n=4) and hospitals (n=4) across four Health and Social 137 
Care (HSC) Trusts in NI. Eligible participants were physicians with responsibility for 138 
managing pain in patients with advanced dementia who had died or who were 139 
approaching the end of life.  140 
 141 
Sampling and recruitment 142 
A pragmatic approach to sampling was taken in light of the number of practising 143 
physicians in NI and the range of medical specialities, departments and care settings in 144 
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which people with dementia at end of life may be managed, and following a review of 145 
sampling frames used in similar studies (37).  146 
Seven General Practitioners (GPs) who participated in previous research with members 147 
of the research team (Project Management Group [PMG]) were asked to disseminate 148 
study information to colleagues in a process of onward referral. In acute care, four 149 
consultants (each within a different HSC Trust region) from geriatric medicine (n=2), 150 
palliative medicine (n=1) and psychiatry (n=1) disseminated study information to eligible 151 
hospital physicians within their HSC catchment area. Four Medical Directors (one in each 152 
of the participating hospices) circulated study information to hospice physicians. All 153 
physicians who contacted the first author regarding participation were recruited to the 154 
study. Physicians who assisted with dissemination of study information did not participate 155 
in the study.  156 
 157 
Ethical approval 158 
The Office for Research Ethics Committees Northern Ireland (ORECNI) granted ethical 159 
approval for the study (14/NI/0013). The study protocol and supporting materials were 160 
also approved by hospice ethics committees and HSC Trusts.  161 
 162 
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Study design and data collection 163 
Semi-structured, in-person interviews were conducted using an interview guide which 164 
allowed flexible exploration of individual experiences within an overarching structure by 165 
which commonalities of experience could be identified (38). Interview questions were 166 
developed following review of relevant literature and refined in an iterative process of 167 
consultation and revision with the PMG which included primary, secondary and hospice 168 
care physicians and academics from nursing, palliative care, geriatric medicine and 169 
pharmacy. Questions covered: approaches to pain management in people with advanced 170 
dementia approaching the end of life, barriers to and facilitators of prescribing for pain 171 
and administering analgesics, and training and education needs. The topic guide is 172 
presented in Table 1.  173 
Physicians were interviewed in their workplace and received Continuing Professional 174 
Development (CPD) certificates for participation. Interviews began with a brief 175 
exposition of the study aims and objectives, and explanations of ethical approval and the 176 
interview process. Each participant provided written, informed consent. Recruitment 177 
continued until no further novel data were identified in interviews.  178 
 179 
Data analysis and validation 180 
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Data were collected between June 2014 and September 2015.  Interviews were conducted, 181 
digitally recorded, transcribed verbatim and analysed by the first author, a researcher with 182 
five years’ prior training in and experience of designing and conducting qualitative 183 
research. Interview duration was on average 18 minutes. Transcripts were checked for 184 
accuracy against recordings by KB and HB. Braun and Clarke’s paradigm of thematic 185 
analysis formed the analytical approach (39). Transcripts were reread several times and 186 
line-by-line coding performed to identify recurrent ideas, statements, feelings/sentiments, 187 
topics and key words. The first ten scripts were reviewed to ensure that coding uniformly 188 
expressed the same ideas, concepts or topics, and a coding frame was developed. Codes 189 
from all transcripts were categorised into themes expressing their core concepts. NVivo 190 
10 (QSR International (UK) Ltd, Cheshire, UK) software was used to facilitate analysis. 191 
Data were independently analysed and verified by KB and CP. Final themes and findings 192 
were discussed by the PMG.  193 
 194 
Results 195 
Twenty-three physicians participated. Physicians’ average age was 42.5 years (range 28 196 
to 58 years), and they had an average of 17.5 years’ clinical experience (range 5 years to 197 
31 years). Most were female (n=16; 69.6%). Six (26.1%) had additional postgraduate 198 
qualifications. Participant characteristics are presented in Table 2.  199 
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Six key themes emerged from the interviews: (1) diagnosing pain, (2) complex 200 
prescribing and treatment approaches, (3) side-effects and adverse events, (4) route of 201 
administration, (5) sharing knowledge and (6) training needs.  202 
 203 
Diagnosing pain 204 
Difficulty diagnosing pain was the most commonly reported barrier to managing pain 205 
appropriately in people with advanced dementia approaching the end of life. Loss of the 206 
critical patient-physician pain dialogue and the absence of any obvious physical cause of 207 
pain (e.g. fracture, wounds) or painful comorbid condition (e.g. cancer) made it difficult 208 
to identify and characterise pain.  209 
 210 
In a patient with dementia, if you have no history or communication from the 211 
patient, it’s impossible to get an accurate history to be able to identify the character 212 
of pain in the way you would be with a patient who could communicate and had 213 
understanding. (PHYS011, GP) 214 
 215 
In the absence of patient report, respondents observed for, and interpreted, behavioural 216 
and nonverbal signs. All respondents were acutely aware of the limitations of this 217 
13 
 
approach, recognising that many of these indicators could also be expressions of fear, 218 
anxiety and other non-pain related distress. Most expressed concern regarding potential 219 
misinterpretation of these cues and advocated caution in relying on this information.  220 
 221 
The signs of pain in this particular patient group could be signs of something else 222 
as well, and that’s where you have to be very careful to recognise what is their 223 
normal behaviour and what has changed or what can we link to pain. (PHYS012, 224 
Consultant in Palliative Care, Hospice) 225 
 226 
The presence of neuropsychiatric symptoms in these patients further complicated pain 227 
diagnosis. Some participants highlighted the potential for misinterpretation of these cues 228 
to result in inappropriate treatment, for example, pain relief for emotional distress, whilst 229 
others reported uncertainty in decisions to treat the patient for (presumed) pain or for the 230 
manifested psychiatric symptoms.  231 
 232 
 Saw a patient yesterday or two days ago who appeared to be in pain, she had 233 
advanced dementia, I felt she was in the last days of her life and she was lying on 234 
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the bed occasionally agitated, throwing her arm up around her head. Hard to know 235 
if that’s pain or not. So do I treat her for pain in that scenario? (PHYS019, GP) 236 
 237 
Complex prescribing and treatment approaches 238 
The impact of complex comorbidity profiles, neurodegenerative disease, low body mass 239 
index and ageing physiology on the pharmacodynamics and pharmacokinetics of many 240 
analgesics were key considerations for physicians.  241 
 242 
In the very severe stages we get people who can be very, very, physically failed 243 
and frail, very low body mass, really no musculature, usually sort of dehydrated, 244 
usually with sort of poor cardiac output. Often we’re not actually sure how much 245 
pain relief is getting in to somebody. Often the difference between what you think 246 
the analgesic’s going to be and what it actually does to a patient in that kind of 247 
stage—the difference is quite substantial. (PHYS03, Consultant Psychiatrist, 248 
Secondary Care) 249 
 250 
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Participants described past experiences in which analgesic effects had been highly 251 
unpredictable, resulting in over-treatment for some patients, poor pain control in others 252 
and adverse events for a minority. 253 
I’ve had it where I’ve given one big fellow a very strong painkiller and it floored 254 
him; I’ve seen a wee lady half the size and very frail and actually it wasn’t working 255 
on her at all. So although I assumed little old ladies need less, it actually went the 256 
opposite way. It’s really very individual, like with everything, everybody’s 257 
different (PHYS011, GP). 258 
 259 
Most respondents therefore exercised caution in prescribing, particularly when treating 260 
new patients, and many followed the principle ‘start low and go slow’ using paracetamol 261 
(acetaminophen) as the preferred first-line treatment, particularly in cases where pain 262 
diagnosis was ambiguous.  263 
 264 
I would start off with maybe a trial of analgesia but I would start off with the 265 
mildest form like paracetamol or something just to see if it made a difference. If 266 
they seemed to be responding, I suppose I would use the WHO analgesia ladder 267 
and just come up very, very cautiously. (PHYS04, GP) 268 
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 269 
Pain management was often described as a ‘trial and error’ process in which pain relief 270 
was titrated in response to changes in behaviour, nonverbal cues, vocalisation and levels 271 
of consciousness. Psychiatrists and GPs found the World Health Organisation (WHO) 272 
Analgesic Ladder (40) helpful in guiding upwards titration; hospice physicians relied on 273 
their own previous clinical experience and consultation with colleagues and preferred the 274 
national Palliative Adult Network Guidelines (PANG) (41). All physicians regularly 275 
prescribed a wide range of analgesics including opioid and compound opioid preparations 276 
in a variety of formulations including transdermal patches, intramuscular injections and 277 
syringe drivers. GPs and psychiatrists often sought advice or confirmation from 278 
specialists such as community hospice, palliative medicine and psychogeriatric 279 
practitioners when titrating to higher doses.  280 
 281 
If these patients are already on medication for pain it’s like where do you go to 282 
augment and increase it? So having input from people who are specialists is always 283 
appreciated. (PHSY014, Psychiatrist, Secondary Care) 284 
 285 
Side-effects and adverse events 286 
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Participants described the challenge of prescribing for patients with advanced dementia 287 
nearing the end of life as a ‘catch-22’ situation in which multiple symptom control 288 
(including pain), was required, with minimal polypharmacy and avoiding drug 289 
interactions and adverse and/or side-effects.  290 
 291 
There’s a catch twenty-two, there’s potential for a lot of interactions with the other 292 
medication that they are on, then you face the difficulty with the side effects of 293 
medications. So it’s really about hitting the balance of making sure that you’re 294 
doing the patient no harm and treating their pain. It’s finding that fine line 295 
(PHYS07, Psychiatrist, Secondary Care) 296 
 297 
Many patients required a greater degree of pain control than could be provided by 298 
paracetamol and other simple analgesics, however; codeine and other opioid-based 299 
preparations were deemed to carry a high risk of respiratory depression, sedation, 300 
constipation and falls, whilst non-steroidal anti-inflammatory drugs (NSAIDs) were 301 
associated with risk of gastric bleeding, cardiovascular and stroke events. Side-effects 302 
such as constipation (a trigger for onset of acute delirium) and nausea (difficult to detect 303 
in the absence of patient self-report), respiratory depression and sedation were considered 304 
highly detrimental to patients and contravened participants’ goals of care.  305 
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 306 
 The likes of the more codeine-based [preparations], it’s the risk of them becoming 307 
constipated and making things worse and then I suppose the more heavy 308 
morphines and so on, it can just floor them, really wipe them off their feet, more 309 
prone to more falls, makes them more drowsy. (PHYS06, Psychiatrist, Secondary 310 
Care) 311 
 312 
Most participants reported that these factors restricted choice of suitable analgesics and 313 
often resulted in off-label prescribing. Many GPs and psychiatrists found this challenging 314 
due to unfamiliarity with off-label uses for palliative purposes, requiring guidance from 315 
palliative care specialists.  316 
  317 
[Palliative care] has taught me things about using certain agents, midazolam, for 318 
example … something that isn’t used widely in my world but it’s used widely in 319 
[the] palliative world. (PHYS09, Consultant Psychiatrist, Secondary Care) 320 
 321 
Route of administration  322 
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All participants reported challenges with routes of administration for patients with 323 
dementia approaching the end of life. Oral administration was compromised in patients 324 
with significant swallowing difficulties, poor gut absorption, nausea and/or vomiting, 325 
impaired consciousness (sedation, coma, sleep or drowsiness), or who refused to take 326 
medication.  327 
 328 
… so perhaps liquids might be refused, tablets may not be taken, they may not be 329 
able to take anything orally and they may need medication by a different route. 330 
(PHYS015, Consultant in Palliative Care, Hospice)  331 
 332 
Many respondents described difficulty encouraging compliance in patients who lacked 333 
capacity to engage in discussion regarding the need for symptom control. Syringe drivers, 334 
normally considered when oral administration is not viable, presented a number of 335 
complications including: forceful removal by agitated patients, lack of available staff 336 
experienced in their set-up and use; and in some cases, lack of access to necessary 337 
equipment or resources.  338 
 339 
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Intravenous [administration] I would have to say we actually rarely use. The 340 
problems being that maintaining venous access in somebody who’s failing is a 341 
problem, it’s often painful and distressing for patient and we open up then risks of 342 
infection and so on as well. So we often try and go for, for subcuts if we can, or 343 
patches. (PHYS03, Consultant Psychiatrist, Secondary Care) 344 
 345 
Transdermal patches were a preferred route for overcoming the challenges posed by oral 346 
and syringe driver routes.  347 
 348 
We’re maybe more likely to use medications administered by patch through the 349 
skin rather than tablets because it’s felt to override the challenges of patients being 350 
able to take their oral medication reliably. (PHYS017, Consultant in Palliative 351 
Care, Hospice) 352 
 353 
Transdermal patches were considered particularly suitable for agitated patients due to their 354 
unobtrusive and non-invasive nature and for avoiding difficulties associated with pro-re-355 
nata (PRN) prescribing in non-verbal patients.  356 
 357 
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We would try and use patches sometimes because they’re less noticeable to the 358 
patient, and if the pain is more stable that can be a way around it. (PHYS015 359 
Consultant in Palliative Care, Hospice) 360 
 361 
Physicians, particularly GPs, highlighted the importance of selecting a route of 362 
administration appropriate to a patient’s health status and needs, and the need to ensure 363 
the availability of healthcare staff appropriately trained to administer and monitor 364 
medication via that route.  365 
 366 
You’ve an issue with trying to select the type of medication you’re going to use 367 
and you’ve an issue then with what way you’re going to administer it to them and 368 
then who’s going to manage that and monitor it as well. (PHYS022, GP) 369 
 370 
Sharing knowledge  371 
All respondents strongly believed that the care of people with dementia approaching the 372 
end of life, including pain management, required input from families and healthcare 373 
professionals across disciplines. Physicians believed their key responsibility was to 374 
provide optimal care for their patients, which included recognising and addressing their 375 
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own limitations. Narratives revealed an interactive interface across primary, secondary 376 
and hospice care settings and medical specialties through which knowledge and expertise 377 
were exchanged.  378 
 379 
When it comes to end of life then, we’re sharing knowledge, we’re the experts in 380 
antipsychotic medications and they [palliative medicine physicians] are finding 381 
that with people with challenging behaviour, they may need to go that route so 382 
we’re sharing in terms of cross-populating our knowledge base. (PHYS09, 383 
Consultant Psychiatrist, Secondary Care) 384 
 385 
GPs and psychiatrists sought advice from palliative and hospice care physicians and 386 
psychogeriatricians regarding: off-label use of analgesics; titration for patients already 387 
receiving pain relief; use of opioid preparations; combining pain-relieving agents; 388 
combining analgesics with mild sedation; managing background or breakthrough pain; 389 
and routes of administration. Hospice physicians sought guidance for particularly 390 
complex patients from neurology, psychogeriatrics, palliative pharmacy and psychiatry. 391 
In many cases, participants wanted confirmation of their proposed treatment; receiving 392 
support from other specialties and knowing they were ‘on the right track’ with prescribing 393 
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and treatment increased confidence and job satisfaction. Many enjoyed learning from and 394 
sharing their expertise with other doctors outside their care setting and medical specialty.  395 
 396 
I would ring, for example, [the hospice] and speak to one of the consultants and I 397 
would ask “This is what I’m thinking of doing, do you think this sounds okay?” 398 
And then I would get that advice. It just gives me that bit more confidence that the 399 
patient’s getting maybe the best they could get; because I don’t think I’m the best, 400 
I think I’m a GP and I think a palliative care consultant would be the best. 401 
(PHYS08, GP) 402 
 403 
Families were perceived to hold key collateral information such as patients’ former beliefs 404 
about medications, previous pain thresholds, whether they were likely to report pain or 405 
‘suffer in silence’, drug tolerance and allergies, behavioural and nonverbal indicators of 406 
pain, and preferred methods of medication delivery.  407 
 408 
We very much work with the families because the families usually know this 409 
person to the point that they know what they maybe would have wanted or how 410 
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they are going to respond so we try and get everybody in on the decision-making. 411 
(PHYS012, Consultant in Palliative Care, Hospice) 412 
 413 
Physicians used this knowledge to inform prescribing decisions and to assess treatment 414 
response.  415 
 416 
One thing is us giving the families information but the other thing is asking them 417 
their perception of whether they perceive that something has helped or not and 418 
whether they have noticed any signs of side-effects. They’re just better placed—if 419 
they’re with the person a lot, to identify whether or not the medication has made 420 
them confused or that kind of thing. (PHYS017, Consultant in Palliative Care, 421 
Hospice) 422 
 423 
Training needs 424 
Physicians were dedicated to providing optimal care for patients often within multiple 425 
organisational constraints. All respondents believed that the knowledge, skills and 426 
expertise required to optimally manage pain in this complex patient population existed 427 
within the health professions but were highly dispersed across medical and other 428 
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disciplines and care-settings. Physicians considered pharmacology, 429 
pharmacotherapeutics, managing pain in patients with challenging behaviours, and 430 
distinguishing between pain-related and non-pain related behavioural and psychological 431 
symptoms of dementia (BSPD), to be key areas for further training. The majority 432 
described physician-to-physician mentoring, in the form of regular meetings of an 433 
established network of practitioners from across care settings and disciplines to discuss 434 
anonymised real patient cases, as an ideal approach to ongoing professional development.  435 
 436 
The best would be experiential learning where you can go on a ward round, discuss 437 
a case, ask questions, that’s the gold standard. (PHYS012, Consultant in Palliative 438 
Care, Hospice) 439 
 440 
Physicians widely believed that this approach would have greater clinical utility and 441 
impact than workshops, training days or didactic lectures.  442 
 443 
I think that case-based learning is useful because I think it gets people to think 444 
about what they do themselves and how they would manage a particular problem. 445 
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I think that has more relevance and power in terms of changing what people do for 446 
the better. (PHYS015, Consultant in Palliative Care, Hospice) 447 
 448 
Discussion  449 
To our knowledge this is the first comprehensive exploration of the challenges in pain 450 
management for people with advanced dementia approaching the end of life, from 451 
physicians’ perspectives. People with advanced dementia require the same vigilance in 452 
pain management as patients dying with terminal cancer; however, available guidelines 453 
offer little advice on how this may be achieved (42-43). Pain control in this patient 454 
population can be difficult to achieve and the findings presented here offer greater insight 455 
into these challenges from the perspectives of those primarily responsible for this aspect 456 
of patient management (44).  457 
The gold standard in diagnosing pain is self-report. In advanced dementia, this is rarely 458 
available; much of the critical information required to accurately assess, diagnose and 459 
target treatment is lost (45). The findings of this study indicate that in the absence of 460 
patient report, collateral history from patients’ families and other health professionals, 461 
along with clinical investigation and interpretation of changes in mood, behaviour, and 462 
other nonverbal cues, become important (45-46). However, participants widely 463 
acknowledged that many well-recognised behavioural indicators of pain, such as distress, 464 
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agitation, wailing, screaming, frowning and apathy, are identical to those expressed 465 
through anxiety, boredom, frustration and emotional distress (47). Behavioural 466 
interpretation leaves room for misinterpretation and potentially inappropriate treatment 467 
(47). Physicians’ prescribing decisions were also shaped by patients’ comorbidities, 468 
ageing physiology, existing medication regimens, physical and cognitive impairments and 469 
health status, which were perceived to restrict the range and strengths of analgesics that 470 
may be safely tolerated (48). Changes in drug pharmacokinetics and pharmacodynamics, 471 
and variation in gut absorption and body fat index may result in over-treatment, delayed 472 
effects of pain relief and increased risk of side-effects and adverse events, making 473 
management complex and uncertain (48). Most physicians adopted a cautious approach 474 
to management. Route of administration was reported as problematic in severely 475 
cognitively impaired, dying patients. Loss of swallow, patient refusal and altered 476 
consciousness often precluded oral administration, whilst syringe driver use was 477 
problematic due to forceful removal by agitated or distressed patients and issues regarding 478 
availability of appropriately experienced nursing staff to set up and monitor the 479 
equipment. Medication delivery via the transdermal route was considered a better 480 
alternative.   481 
Physicians across specialties and care settings often sought and shared advice and 482 
approaches to pain management. Most respondents strongly believed ongoing CPD via 483 
mentoring and knowledge exchange using real-patient cases would empower non-484 
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palliative specialists to effectively manage patients approaching the end of life. Previous 485 
studies have identified a need for further training for healthcare professionals in 486 
pharmacology and the use of nonpharmacological treatments, and in discriminating 487 
between behavioural and psychological symptoms caused by pain and those which are not 488 
pain-related in origin (44,49). The present findings corroborate these suggestions, and 489 
provide additional insight into physicians’ training preferences.  490 
Sharing knowledge extended beyond health professionals; most participants found 491 
collateral history provided by families to be helpful in assessing pain and interpreting 492 
nonverbal cues. This echoes other studies which report that good communication, shared 493 
knowledge and a mutually respectful relationship between the healthcare team and family 494 
carers are critical if treatment is to reflect the interests of the dying patient and achieve 495 
clinical goals of care (50-51). Some of the above findings echo those reported in the 496 
nursing literature, indicating that medical, nursing and other healthcare staff experience 497 
similar challenges in assessment and management of pain for patients with dementia and 498 
emphasising the need for effective multidisciplinary working and open communication 499 
between healthcare professionals (52-55). 500 
There are some limitations with this study. The sampling approach may have resulted in 501 
a skewed sample of physicians with an interest in, or past experience of, research 502 
participation, who felt comfortable talking about professional challenges. We aimed to 503 
recruit physicians across acute specialties; the low participation by physicians outside 504 
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psychiatry (possibly due to staffing pressures and workloads) is an acknowledged 505 
limitation. Future studies might consider exploring physicians’ approaches to pain 506 
management for people with advanced dementia with a broader sample of acute 507 
physicians. The findings of this study are being used to develop and pilot an intervention 508 
aimed at bringing together physicians and other health professionals to engage in 509 
interactive real patient case-based learning. It is hoped these findings may encourage 510 
further development of strategies to support and empower physicians to provide a gold 511 
standard in managing pain for people living and dying with dementia.  512 
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